|
|
Résultats pour
 brevets
1.
|
Protein and protein conjugate for diabetes treatment, and applications thereof
| Numéro d'application |
16566455 |
| Numéro de brevet |
11208451 |
| Statut |
Délivré - en vigueur |
| Date de dépôt |
2019-09-10 |
| Date de la première publication |
2020-01-02 |
| Date d'octroi |
2021-12-28 |
| Propriétaire |
- ADDA Biotech Inc. (USA)
- Han Jie (USA)
|
| Inventeur(s) |
|
Abrégé
The present invention relates to the field of biopharmaceuticals, and in particular to a protein, a protein conjugate, a pharmaceutical composition and its use for treating diabetes. The fusion protein of the present invention is obtained by linking two polypeptides, wherein one polypeptide is an interleukin-1 receptor antagonistic protein or an analogue thereof, and another polypeptide is GLP-1 receptor binding polypeptide or an analogue thereof, or an insulin receptor binding polypeptide or an analogue thereof, or a GIP receptor binding polypeptide or an analogue thereof. The fusion proteins of the present invention and conjugates thereof have a significant efficacy in treating diabetes, and can be used in a lower dose, resulting in marked reduction in side effects.
|
2.
|
Protein and protein conjugate for diabetes treatment, and applications thereof
| Numéro d'application |
15585655 |
| Numéro de brevet |
10472404 |
| Statut |
Délivré - en vigueur |
| Date de dépôt |
2017-05-03 |
| Date de la première publication |
2017-08-17 |
| Date d'octroi |
2019-11-12 |
| Propriétaire |
- ADDA Biotech Inc. (Chine)
- Han Jie (Chine)
|
| Inventeur(s) |
|
Abrégé
The present invention relates to the field of biopharmaceuticals, and in particular to a protein, a protein conjugate, a pharmaceutical composition and its use for treating diabetes. The fusion protein of the present invention is obtained by linking two polypeptides, wherein one polypeptide is an interleukin-1 receptor antagonistic protein or an analogue thereof, and another polypeptide is GLP-1 receptor binding polypeptide or an analogue thereof, or an insulin receptor binding polypeptide or an analogue thereof, or a GIP receptor binding polypeptide or an analogue thereof. The fusion proteins of the present invention and conjugates thereof have a significant efficacy in treating diabetes, and can be used in a lower dose, resulting in marked reduction in side effects.
|
3.
|
Protein and protein conjugate for diabetes treatment, and applications thereof
| Numéro d'application |
14402074 |
| Numéro de brevet |
09745359 |
| Statut |
Délivré - en vigueur |
| Date de dépôt |
2013-05-17 |
| Date de la première publication |
2015-07-02 |
| Date d'octroi |
2017-08-29 |
| Propriétaire |
ADDA Biotech Inc. (Chine)
|
| Inventeur(s) |
Qin, Shulin
|
Abrégé
The present invention relates to the field of biopharmaceutics, and in particular to a protein, a protein conjugate, a pharmaceutical composition and its use for treating diabetes. The fusion protein of the present invention is obtained by linking two polypeptides, wherein one polypeptide is an interleukin-1 receptor antagonistic protein or an analog thereof, and another polypeptide is GLP-1 receptor binding polypeptide or an analog thereof, or an insulin receptor binding polypeptide or an analog thereof, or a GIP receptor binding polypeptide or an analog thereof. The fusion proteins of the present invention and conjugates thereof have a significant efficacy in treating diabetes, and can be used in a lower dose, resulting in a marked reduction in side effects.
|
4.
|
PROTEIN AND PROTEIN CONJUGATE FOR DIABETES TREATMENT, AND APPLICATIONS THEREOF
| Numéro d'application |
CN2013000587 |
| Numéro de publication |
2013/170636 |
| Statut |
Délivré - en vigueur |
| Date de dépôt |
2013-05-17 |
| Date de publication |
2013-11-21 |
| Propriétaire |
ADDA BIOTECH INC. (Chine)
|
| Inventeur(s) |
Qin, Shulin
|
Abrégé
The present invention relates to the field of bio-pharmaceuticals, and relates to a protein, a protein conjugate, a pharmaceutical composition for diabetes treatment, and applications thereof. A fusion protein of the present invention consists of two polypeptides connected with each other. One of the polypeptides is interleukin-1 receptor antagonist protein or an analogue thereof, and the other polypeptide is GLP-1 receptor binding polypeptide or an analogue thereof, or insulin receptor binding polypeptide or an analogue thereof, or a GIP receptor binding polypeptide or an analogue thereof. The fusion protein and the conjugate thereof of the present invention have an obvious effect in treating diabetes; in addition, the dosage is small, and the side effect on users is significantly alleviated.
Classes IPC ?
- C12N 15/62 - Séquences d'ADN codant pour des protéines de fusion
- C07K 19/00 - Peptides hybrides
- C07K 14/545 - IL-1
- C07K 14/605 - Glucagons
- C07K 14/595 - GastrinesCholécystokinines [CCK]
- A61K 38/16 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés
- A61K 38/30 - Facteurs de croissance analogues à l'insuline, c.-à-d. somatomédines, p. ex. IGF-1, IGF-2
- A61K 38/26 - Glucagons
- A61P 3/10 - Médicaments pour le traitement des troubles du métabolisme de l'homéostase du glucose de l'hyperglycémie, p. ex. antidiabétiques
|
5.
|
COMPOUND AND COMPOSITION HAVING HYPOGLYCEMIC EFFECT AND USE THEREOF
| Numéro d'application |
CN2012001700 |
| Numéro de publication |
2013/086786 |
| Statut |
Délivré - en vigueur |
| Date de dépôt |
2012-12-14 |
| Date de publication |
2013-06-20 |
| Propriétaire |
ADDA BIOTECH INC. (Chine)
|
| Inventeur(s) |
Qin, Shulin
|
Abrégé
Provided in the present invention are a compound and composition having hypoglycemic effect, and an application of the compound or composition in treating diabetes and hyperglycemia. Also provided in the present invention is a method for treating diabetes and hyperglycemia, comprising administration to patients in need of the compound or composition of the present invention. Compared to existing insulin and other analogues, the compound of the present invention has great aqueous solubility, long in vivo cycle, high activity for combining with an insulin receptor, significantly reduced toxic effect on individuals, and is easy to prepare.
Classes IPC ?
- C07K 14/62 - Insulines
- A61K 38/28 - Insulines
- A61P 3/10 - Médicaments pour le traitement des troubles du métabolisme de l'homéostase du glucose de l'hyperglycémie, p. ex. antidiabétiques
|
6.
|
COMPOUND AND COMPOSITION HAVING HYPOGLYCEMIC EFFECT AND USE THEREOF
| Numéro d'application |
CN2012001699 |
| Numéro de publication |
2013/086785 |
| Statut |
Délivré - en vigueur |
| Date de dépôt |
2012-12-14 |
| Date de publication |
2013-06-20 |
| Propriétaire |
ADDA BIOTECH INC. (Chine)
|
| Inventeur(s) |
Qin, Shulin
|
Abrégé
Provided in the present invention are a compound and composition having hypoglycemic effect, and an application of the compound or composition in treating diabetes and hyperglycemia. Also provided in the present invention is a method for treating diabetes and hyperglycemia, comprising administration to patients in need of the compound or composition of the present invention. Compared to existing insulin and other analogues, the compound of the present invention has great aqueous solubility, long in vivo cycle, high activity for combining with an insulin receptor, significantly reduced toxic effect on individuals, and is easy to prepare.
Classes IPC ?
- C07K 14/65 - Facteurs de croissance analogues à l'insuline, c.-à-d. somatomédines, p. ex. IGF-1, IGF-2
- A61K 38/30 - Facteurs de croissance analogues à l'insuline, c.-à-d. somatomédines, p. ex. IGF-1, IGF-2
- A61P 3/10 - Médicaments pour le traitement des troubles du métabolisme de l'homéostase du glucose de l'hyperglycémie, p. ex. antidiabétiques
|
|